Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.00 and traded as high as $0.0004. Nascent Biotech shares last traded at $0.0004, with a volume of 1,000 shares.
Nascent Biotech Trading Up 33.3%
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.
See Also
- Five stocks we like better than Nascent Biotech
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
